Treatment with Allogenic Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome: A Double-Blind, Placebo-controlled, Multi-Center, Phase 2b Clinical Trial (STAT).

Journal:

American Journal of Respiratory and Critical Care Medicine

Published:

2025-07-30

DOI:

10.1164/rccm.202411-2254oc

Affiliations:

32

Authors:

33

Go to article

Institutions	Authors	Share
University of California, San Francisco (UCSF), United States of America (USA)	12.000000 12.000000	0.36
The University of Texas Health Science Center at Houston (UTHealth), United States of America (USA)	9.000000	0.27
Oregon Health and Science University (OHSU), United States of America (USA)	3.000000	0.09
Vanderbilt University Medical Center (VUMC), United States of America (USA)	2.000000	0.06
Harborview Medical Center (HMC), United States of America (USA)	1.000000	0.03
University of California, Davis (UC Davis), United States of America (USA)	1.000000	0.03
University of Minnesota (UMN), United States of America (USA)	1.000000	0.03
UW Medicine, United States of America (USA)	1.000000	0.03
Vanderbilt University (VU), United States of America (USA)	1.000000	0.03
Zuckerberg San Francisco General Hospital and Trauma Center (ZSFG), United States of America (USA)	1.000000	0.03
UC Davis Medical Center (UCDMC), United States of America (USA)	1.000000	0.03

Interested in Medical Biotechnology?